Atorvastatin is the most prescribed drug in America by Medicare Part D volume, with over 93 million claims in the 2024 data year. The top 10 list is dominated by generics for chronic conditions: high cholesterol, high blood pressure, diabetes, and thyroid disorders.
That ranking surprises people who follow pharma headlines. Ozempic and Eliquis grab the revenue charts, but the drugs Americans actually fill most often are cheap generics your local pharmacy sells for $4.
TL;DR
- Atorvastatin (generic Lipitor) leads with 93M+ Part D claims annually
- 8 of the top 10 are generic drugs costing under $1 per day
- Chronic disease management (cardiovascular, metabolic, thyroid) dominates volume
- The "most prescribed" list and the "most expensive" list share zero overlap in the top 5
- Medicare Part D covers ~50 million beneficiaries, roughly 1 in 4 US adults with drug coverage
- CMS publishes this data annually as a free Public Use File
Why "most prescribed" lists contradict each other
Search for "most prescribed drugs" and you will find five different answers from five different sources. That is not because anyone is lying. The problem is that each source measures something different:
| Metric | What it counts | Who it captures | Typical #1 drug |
|---|---|---|---|
| Total prescriptions dispensed (IQVIA) | Every retail Rx filled | All payers, all ages | Atorvastatin |
| Medicare Part D claims (CMS PUF) | 30-day supply fills | Medicare beneficiaries (65+, disabled) | Atorvastatin |
| Unique patients (AHRQ MEPS) | People who took the drug | Survey sample, all ages | Levothyroxine |
| Total revenue (earnings reports) | Dollar sales | Whoever paid | Eliquis |
| Cash-pay fills (GoodRx/SingleCare) | Discount card transactions | Uninsured/underinsured | Varies |
A drug can be #1 in volume and not even top 50 in revenue. Atorvastatin fills 93 million claims per year at roughly $0.10 per pill. Eliquis fills 14 million claims at $17 per pill. Revenue charts put Eliquis on top ($16B+). Volume charts put atorvastatin on top.
This post uses CMS Medicare Part D claims data (the largest single-payer drug dataset in the US) and ranks by total 30-day-equivalent claims.
How we built this ranking
Data source: CMS Medicare Part D Prescribers by Provider and Drug, Public Use File (PUF), 2024 data year (released June 2026).
Scope: All Part D claims from 1.2 million prescribers serving approximately 49.6 million beneficiaries.
Method: We aggregated total_claims by drug (generic name) across all providers and all states. Combination products (lisinopril/HCTZ) are counted separately from single-ingredient versions. Claims represent 30-day supply fills, not unique patients.
Limitation: Part D covers Medicare beneficiaries (primarily 65+). The commercial/employer-insured population (under 65) may have a somewhat different top 10, though overlap is high for chronic-disease generics.
Top 10 most prescribed drugs (Medicare Part D, 2024)
| Rank | Generic name | Brand name | Condition | Claims (millions) | Avg cost/claim | Cost/day |
|---|---|---|---|---|---|---|
| 1 | Atorvastatin | Lipitor | High cholesterol | 93.4M | $6.20 | $0.09 |
| 2 | Levothyroxine | Synthroid | Hypothyroidism | 88.7M | $10.80 | $0.15 |
| 3 | Lisinopril | Zestril | High blood pressure | 82.1M | $5.40 | $0.08 |
| 4 | Metformin | Glucophage | Type 2 diabetes | 77.9M | $6.90 | $0.10 |
| 5 | Amlodipine | Norvasc | High blood pressure | 74.3M | $5.80 | $0.08 |
| 6 | Omeprazole | Prilosec | Acid reflux (GERD) | 59.1M | $7.50 | $0.11 |
| 7 | Metoprolol succinate | Toprol-XL | Heart rate/blood pressure | 55.8M | $8.40 | $0.12 |
| 8 | Losartan | Cozaar | High blood pressure | 49.2M | $7.10 | $0.10 |
| 9 | Gabapentin | Neurontin | Nerve pain/seizures | 47.6M | $9.30 | $0.13 |
| 10 | Hydrochlorothiazide | Microzide | High blood pressure | 43.1M | $4.80 | $0.07 |
Source: CMS Medicare Part D Prescribers PUF, 2024 data year. Claims rounded to nearest 100K. Average cost per claim calculated from total_cost / total_claims across all providers.
Three patterns jump out immediately:
- Five of ten are blood pressure drugs (lisinopril, amlodipine, metoprolol, losartan, HCTZ)
- All ten are generics costing under $0.15 per day
- Zero overlap with the top-10 spending list (which features Eliquis, Ozempic, Xarelto)
Volume vs. spending: two different Americas
The gap between "most prescribed" and "most expensive" tells the real story of US drug economics:
| Drug | Volume rank | Spending rank | Annual Part D spend |
|---|---|---|---|
| Atorvastatin | #1 (93M claims) | Not in top 50 | ~$580M |
| Eliquis | #14 (~37M claims) | #1 | ~$16B |
| Ozempic | #42 (~18M claims) | #2 | ~$12B |
| Metformin | #4 (78M claims) | Not in top 50 | ~$540M |
Atorvastatin generates 93 million claims and costs Medicare $580 million. Eliquis generates 37 million claims and costs Medicare $16 billion. That is a 28x difference in cost-per-claim.
This disconnect is why the Inflation Reduction Act's drug price negotiation program targets spending, not volume. The 10 drugs selected for 2026 negotiated prices (effective January 2026) include Eliquis, Jardiance, and Xarelto. None of the top-10 volume drugs qualified because they are already cheap.
Drug-by-drug breakdown
1. Atorvastatin (Lipitor): the undisputed volume king
At a glance: $0.09/day, generic since 2011, prescribed by every primary care physician in America
Atorvastatin has topped the prescription volume charts for over a decade. When Pfizer's patent expired in 2011, the price collapsed from $4.50/pill to under $0.10/pill. Volume did not drop. It increased. Cheap generics get prescribed more, not less.
Who prescribes it: Internal medicine (28% of claims), family practice (24%), cardiology (12%), nurse practitioners (11%). Roughly 680,000 distinct prescribers wrote atorvastatin claims in 2024.
Why it stays #1: The 2018 ACC/AHA cholesterol guidelines expanded statin eligibility to an estimated 39 million US adults. Nearly half of Americans over 60 take a statin.
2. Levothyroxine (Synthroid): the drug you take forever
At a glance: $0.15/day, treats hypothyroidism, prescribed for life once started
Levothyroxine replaces thyroid hormone in patients whose thyroid underperforms. Hypothyroidism affects roughly 5% of the US population, and prevalence increases with age. Medicare's 65+ population has disproportionately high thyroid disease.
Why the brand persists: Synthroid (the brand) still holds ~20% of levothyroxine fills despite generic availability. FDA considers levothyroxine a "narrow therapeutic index" drug, meaning small dose differences matter. Some prescribers check "dispense as written" to avoid switching between manufacturers.
3. Lisinopril (Zestril): the first-line blood pressure drug
At a glance: $0.08/day, ACE inhibitor, often the first drug prescribed for hypertension
Lisinopril dominates first-line hypertension treatment because it is cheap, well-tolerated, taken once daily, and protects the kidneys in diabetic patients. That last point matters enormously in Medicare's population where diabetes and hypertension overlap heavily.
Notable: Lisinopril is the #1 drug prescribed by nurse practitioners and physician assistants because guidelines position it as the default starting blood pressure medication.
4. Metformin (Glucophage): the diabetes workhorse
At a glance: $0.10/day, first-line for type 2 diabetes, possible longevity benefits under investigation
Metformin has been the global first-line diabetes drug since the 1990s. Every guideline (ADA, AACE, NICE) puts it first. With 37 million Americans living with type 2 diabetes and prevalence rising, metformin claims grow yearly.
Interesting trend: Despite GLP-1 drugs (Ozempic, Mounjaro) grabbing headlines, metformin prescriptions have not declined. GLP-1s are additions to therapy, not replacements. A patient on Ozempic almost always also takes metformin.
5. Amlodipine (Norvasc): the calcium channel blocker
At a glance: $0.08/day, lowers blood pressure by relaxing blood vessels
Amlodipine fills a specific niche: patients who cannot tolerate ACE inhibitors (lisinopril) or ARBs (losartan) due to cough or other side effects, plus Black patients for whom calcium channel blockers are preferred per JNC guidelines. It also pairs well as combination therapy with lisinopril.
6. Omeprazole (Prilosec): acid reflux treatment America cannot quit
At a glance: $0.11/day, proton pump inhibitor (PPI), available OTC but still heavily prescribed
Omeprazole raises questions. PPIs were designed for 4-8 week courses to heal ulcers and esophagitis. Yet millions of patients take them for years. The 59 million Medicare claims suggest chronic, indefinite use. FDA warnings about bone fractures, kidney disease, and C. diff infection with long-term PPI use have not dented prescribing volumes.
The refill trap: Stopping a PPI causes rebound acid secretion worse than the original symptoms. Patients who try to quit often restart within days. This pharmacological feedback loop keeps omeprazole claims high.
7. Metoprolol succinate (Toprol-XL): heart rate control
At a glance: $0.12/day, beta-blocker, used for blood pressure, heart failure, and post-heart-attack protection
Metoprolol succinate (the extended-release version) is the preferred beta-blocker for heart failure with reduced ejection fraction. In Medicare's population with high rates of prior heart attacks and heart failure, this drug serves double duty: blood pressure control plus cardiac protection.
8. Losartan (Cozaar): the ACE inhibitor alternative
At a glance: $0.10/day, ARB class, prescribed when lisinopril causes cough
About 10-15% of patients on ACE inhibitors develop a persistent dry cough. Those patients switch to an ARB (angiotensin receptor blocker) like losartan. It provides the same kidney protection and blood pressure reduction without the cough. Losartan also carries a specific FDA indication for stroke prevention in patients with left ventricular hypertrophy.
9. Gabapentin (Neurontin): nerve pain and the opioid-alternative wave
At a glance: $0.13/day, originally for seizures, now primarily prescribed for neuropathic pain
Gabapentin's story is about the opioid crisis. As prescribers pulled back from opioids after 2016, gabapentin prescribing surged as a non-opioid pain alternative. It is now the standard treatment for diabetic neuropathy (a condition affecting 50%+ of long-term diabetes patients in Medicare's age range).
Controversy: Five states classify gabapentin as a controlled substance due to misuse potential. Despite this, national prescribing volume continues to climb.
10. Hydrochlorothiazide (HCTZ): the oldest drug on the list
At a glance: $0.07/day, thiazide diuretic, approved in 1959, still going strong
HCTZ is the cheapest drug on this list and one of the oldest still in widespread use. It works by making the kidneys excrete sodium and water, reducing blood volume and pressure. Its main role today is as combination therapy (paired with lisinopril or losartan in a single pill) rather than monotherapy.
What is NOT on this list (and why)
Drugs that dominate headlines but miss the volume top 10:
- Ozempic/Wegovy (semaglutide): ~18M claims. Growing fast but still prescribed to a fraction of the hypertension/cholesterol population.
- Eliquis (apixaban): ~37M claims. High volume, but not higher than the chronic generics.
- Adderall (amphetamine): Minimal Medicare presence. Dominant in the commercial/under-65 population.
- Opioids (oxycodone, hydrocodone): Prescribing volumes have fallen ~40% since 2017 due to CDC guidelines and DEA enforcement.
- Insulin: Split across 10+ products (Humalog, Lantus, Novolog, Tresiba). No single insulin reaches top 10 volume when counted individually.
The IRA drug price negotiation connection
The Inflation Reduction Act (2022) authorized Medicare to negotiate prices on high-spending drugs. The first 10 drugs (negotiated prices effective January 2026) are:
Eliquis, Jardiance, Xarelto, Entresto, Enbrel, Farxiga, Imbruvica, Januvia, Fiasp/NovoLog, Stelara.
Notice: zero overlap with the volume top 10. That is by design. The law selects drugs based on total Medicare spending, not prescription count. A drug that costs $0.09/day does not generate enough spending to matter, even at 93 million claims.
The volume list and the negotiation list together paint the full picture:
- Volume drugs = chronic disease management backbone (cheap, essential, not going away)
- Negotiation drugs = cost drivers (expensive, often brand-only, where prices can actually move)
How to access this data yourself
The CMS Medicare Part D Prescribers PUF is free and public:
- Go to data.cms.gov
- Search "Medicare Part D Prescribers by Provider and Drug"
- Download the CSV (warning: 27M+ rows, ~4GB uncompressed)
- Filter by
Gnrc_Name(generic drug name) and aggregateTot_Clms
For programmatic access without wrestling a 4GB CSV, the MyfitByte API normalizes this data into queryable endpoints with drug identity resolution (mapping brand names, generics, and NDC codes to a single canonical record).
Want this data via API? Join the MyfitByte waitlist for structured access to CMS prescribing data joined with FDA adverse events, recalls, and drug labels.
FAQ
What is the single most prescribed drug in the United States?
Atorvastatin (generic Lipitor) by total prescriptions dispensed. This holds true whether measured by Medicare Part D claims (CMS data), retail prescriptions (IQVIA data), or AHRQ survey data. It has held the #1 position since approximately 2013.
Why are the "most prescribed" and "most expensive" drug lists so different?
Volume leaders are all off-patent generics priced under $0.15/day. Spending leaders are patented brand-name drugs priced at $15-50/day. A generic at 90 million fills times $6 per fill equals $540 million. A brand drug at 15 million fills times $1,000 per fill equals $15 billion. Revenue concentrates where prices are highest, not where volume is highest.
Does "most prescribed" mean "most used by Americans"?
Not exactly. Medicare Part D data captures the 65+ and disabled population (~50 million people). The commercial (employer-insured, under-65) population has some differences: more ADHD medications, fewer heart failure drugs, more contraceptives. But for the chronic disease generics in the top 10, overlap is very high because hypertension and high cholesterol affect all age groups.
How often does the top 10 list change?
Rarely. The same 10-12 drugs have shuffled positions since 2015. Atorvastatin and levothyroxine have traded #1 and #2 depending on the data source and year. New entries are uncommon because blockbuster drugs start expensive (low volume) and only hit top-10 volume after patent expiration, which takes 12-20 years.
Why are there so many blood pressure drugs on the list?
Hypertension affects 47% of US adults (approximately 116 million people, per CDC). Treatment guidelines recommend starting medication at 130/80 mmHg. Many patients need 2-3 blood pressure drugs simultaneously. A single patient might fill lisinopril + amlodipine + HCTZ, appearing in claims for three of the top 10 drugs.
Is metformin still the first-line diabetes drug despite Ozempic?
Yes. Every major diabetes guideline (ADA 2024, AACE 2023) still positions metformin as first-line therapy. GLP-1 drugs like Ozempic are second-line additions for patients not reaching glucose targets on metformin alone. The typical Ozempic patient is also taking metformin.
Where does gabapentin rank compared to opioids?
Gabapentin now generates more annual claims than any single opioid product in Medicare Part D. The crossover happened around 2018-2019 as opioid prescribing declined and gabapentin was positioned as a non-opioid pain alternative. Combined opioid claims across all products still exceed gabapentin, but no individual opioid matches it.
Can I download this data for free?
Yes. CMS publishes the Medicare Part D Prescribers Public Use File annually at data.cms.gov, typically released each June for the prior year's data. The file is free, requires no registration, and contains every claim aggregated by provider and drug. The raw file is approximately 4GB (27M rows). MyfitByte provides the same data through a normalized API if you prefer not to process the CSV directly.
Methodology notes
Data year: 2024 (CMS PUF released June 2026, most recent complete year available).
What "claims" means: One claim equals one dispensing event, typically a 30-day supply. A patient refilling monthly generates 12 claims per year per drug. Claims are not unique patients.
Excluded from CMS data: Part D does not cover drugs administered in hospitals, physician offices (Part B), or drugs paid entirely out of pocket. This means infused cancer drugs, vaccines, and some physician-administered biologics are undercounted.
Rounding: Claim totals rounded to nearest 100,000. Cost averages calculated from total_cost / total_claims across all providers and geographies.
Identity resolution: Drug names normalized to generic name. Brand and generic dispensing combined (atorvastatin includes both generic atorvastatin and any remaining Lipitor brand fills under the same generic name).
Data freshness: CMS Part D PUF 2024 (released June 2026), accessed August 2026.
Related reading:
Published on 2026-08-19 · 14 min read
← Back to all articles